Mind Medicine (MindMed) Inc.
Mind Medicine (MindMed) Inc. MMED.NE Peers
See (MMED.NE) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MMED.NE | CA$14.90 | +9.48% | 1.1B | -4.50 | -CA$3.31 | N/A |
| BLU.TO | CA$19.48 | -0.10% | 2.5B | -20.29 | -CA$0.96 | N/A |
| FRX.TO | CA$11.25 | N/A | 310.7M | -15.41 | -CA$0.73 | N/A |
| DRUG.CN | CA$35.25 | -7.33% | 249.7M | -185.53 | -CA$0.19 | N/A |
| CYBN.NE | CA$10.91 | -1.27% | 229.4M | -2.20 | -CA$4.96 | N/A |
| EPRX.TO | CA$5.34 | -1.29% | 191.4M | -5.13 | -CA$1.04 | N/A |
| MSCL.TO | CA$0.65 | +1.54% | 114.4M | 2.71 | CA$0.24 | N/A |
| GLAB.CN | CA$1.02 | +10.91% | 76.4M | -20.40 | -CA$0.05 | N/A |
| MSET.CN | CA$0.74 | -1.33% | 75M | -12.33 | -CA$0.06 | N/A |
| MDNA.TO | CA$0.95 | -6.86% | 74.3M | -2.64 | -CA$0.36 | N/A |
Stock Comparison
MMED.NE vs BLU.TO Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, BLU.TO has a market cap of 2.5B. Regarding current trading prices, MMED.NE is priced at CA$14.90, while BLU.TO trades at CA$19.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas BLU.TO's P/E ratio is -20.29. In terms of profitability, MMED.NE's ROE is -0.33%, compared to BLU.TO's ROE of -0.22%. Regarding short-term risk, MMED.NE is more volatile compared to BLU.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs FRX.TO Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, FRX.TO has a market cap of 310.7M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while FRX.TO trades at CA$11.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas FRX.TO's P/E ratio is -15.41. In terms of profitability, MMED.NE's ROE is -0.33%, compared to FRX.TO's ROE of +0.19%. Regarding short-term risk, MMED.NE is more volatile compared to FRX.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs DRUG.CN Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, DRUG.CN has a market cap of 249.7M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while DRUG.CN trades at CA$35.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas DRUG.CN's P/E ratio is -185.53. In terms of profitability, MMED.NE's ROE is -0.33%, compared to DRUG.CN's ROE of -0.06%. Regarding short-term risk, MMED.NE is more volatile compared to DRUG.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs CYBN.NE Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, CYBN.NE has a market cap of 229.4M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while CYBN.NE trades at CA$10.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas CYBN.NE's P/E ratio is -2.20. In terms of profitability, MMED.NE's ROE is -0.33%, compared to CYBN.NE's ROE of -0.39%. Regarding short-term risk, MMED.NE is more volatile compared to CYBN.NE. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs EPRX.TO Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, EPRX.TO has a market cap of 191.4M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while EPRX.TO trades at CA$5.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas EPRX.TO's P/E ratio is -5.13. In terms of profitability, MMED.NE's ROE is -0.33%, compared to EPRX.TO's ROE of -1.21%. Regarding short-term risk, MMED.NE is more volatile compared to EPRX.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs MSCL.TO Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, MSCL.TO has a market cap of 114.4M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while MSCL.TO trades at CA$0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas MSCL.TO's P/E ratio is 2.71. In terms of profitability, MMED.NE's ROE is -0.33%, compared to MSCL.TO's ROE of -0.74%. Regarding short-term risk, MMED.NE is more volatile compared to MSCL.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs GLAB.CN Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, GLAB.CN has a market cap of 76.4M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while GLAB.CN trades at CA$1.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas GLAB.CN's P/E ratio is -20.40. In terms of profitability, MMED.NE's ROE is -0.33%, compared to GLAB.CN's ROE of +1.38%. Regarding short-term risk, MMED.NE is more volatile compared to GLAB.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs MSET.CN Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, MSET.CN has a market cap of 75M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while MSET.CN trades at CA$0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas MSET.CN's P/E ratio is -12.33. In terms of profitability, MMED.NE's ROE is -0.33%, compared to MSET.CN's ROE of -3.17%. Regarding short-term risk, Volatility data is not available for a full comparison. MMED.NE has daily volatility of 26.02 and MSET.CN has daily volatility of N/A.
MMED.NE vs MDNA.TO Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, MDNA.TO has a market cap of 74.3M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while MDNA.TO trades at CA$0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas MDNA.TO's P/E ratio is -2.64. In terms of profitability, MMED.NE's ROE is -0.33%, compared to MDNA.TO's ROE of -1.64%. Regarding short-term risk, MMED.NE is more volatile compared to MDNA.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs HBP.TO Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, HBP.TO has a market cap of 68.2M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while HBP.TO trades at CA$0.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas HBP.TO's P/E ratio is -0.88. In terms of profitability, MMED.NE's ROE is -0.33%, compared to HBP.TO's ROE of +21.43%. Regarding short-term risk, MMED.NE is more volatile compared to HBP.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs ONCO.CN Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, ONCO.CN has a market cap of 63.8M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while ONCO.CN trades at CA$1.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas ONCO.CN's P/E ratio is -147.00. In terms of profitability, MMED.NE's ROE is -0.33%, compared to ONCO.CN's ROE of -3.52%. Regarding short-term risk, MMED.NE is more volatile compared to ONCO.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs SVA.TO Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, SVA.TO has a market cap of 57.5M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while SVA.TO trades at CA$0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas SVA.TO's P/E ratio is -1.94. In terms of profitability, MMED.NE's ROE is -0.33%, compared to SVA.TO's ROE of +2.30%. Regarding short-term risk, MMED.NE is more volatile compared to SVA.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs PMN.TO Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, PMN.TO has a market cap of 51.5M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while PMN.TO trades at CA$6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas PMN.TO's P/E ratio is -1.78. In terms of profitability, MMED.NE's ROE is -0.33%, compared to PMN.TO's ROE of -5.57%. Regarding short-term risk, MMED.NE is more volatile compared to PMN.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs MBX.TO Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, MBX.TO has a market cap of 47.9M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while MBX.TO trades at CA$0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas MBX.TO's P/E ratio is 34.00. In terms of profitability, MMED.NE's ROE is -0.33%, compared to MBX.TO's ROE of +0.07%. Regarding short-term risk, MMED.NE is more volatile compared to MBX.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs DTC.CN Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, DTC.CN has a market cap of 42.1M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while DTC.CN trades at CA$0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas DTC.CN's P/E ratio is -9.62. In terms of profitability, MMED.NE's ROE is -0.33%, compared to DTC.CN's ROE of +1.22%. Regarding short-term risk, MMED.NE is more volatile compared to DTC.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs IGX.TO Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, IGX.TO has a market cap of 41.9M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while IGX.TO trades at CA$0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas IGX.TO's P/E ratio is -3.00. In terms of profitability, MMED.NE's ROE is -0.33%, compared to IGX.TO's ROE of +0.39%. Regarding short-term risk, MMED.NE is more volatile compared to IGX.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs ONC.TO Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, ONC.TO has a market cap of 41.7M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while ONC.TO trades at CA$0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas ONC.TO's P/E ratio is -1.17. In terms of profitability, MMED.NE's ROE is -0.33%, compared to ONC.TO's ROE of -2.25%. Regarding short-term risk, MMED.NE is more volatile compared to ONC.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs PREV.CN Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, PREV.CN has a market cap of 38.2M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while PREV.CN trades at CA$0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas PREV.CN's P/E ratio is -45.00. In terms of profitability, MMED.NE's ROE is -0.33%, compared to PREV.CN's ROE of +0.19%. Regarding short-term risk, MMED.NE is more volatile compared to PREV.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs DOSE.CN Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, DOSE.CN has a market cap of 27M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while DOSE.CN trades at CA$0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas DOSE.CN's P/E ratio is -5.25. In terms of profitability, MMED.NE's ROE is -0.33%, compared to DOSE.CN's ROE of +1.61%. Regarding short-term risk, MMED.NE is more volatile compared to DOSE.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs BCT.TO Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, BCT.TO has a market cap of 26.5M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while BCT.TO trades at CA$4.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas BCT.TO's P/E ratio is -0.69. In terms of profitability, MMED.NE's ROE is -0.33%, compared to BCT.TO's ROE of +66.06%. Regarding short-term risk, MMED.NE is more volatile compared to BCT.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs AEZS.TO Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, AEZS.TO has a market cap of 25.4M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while AEZS.TO trades at CA$8.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas AEZS.TO's P/E ratio is -2.61. In terms of profitability, MMED.NE's ROE is -0.33%, compared to AEZS.TO's ROE of -0.67%. Regarding short-term risk, MMED.NE is more volatile compared to AEZS.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs PHRM.CN Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, PHRM.CN has a market cap of 18.6M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while PHRM.CN trades at CA$0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas PHRM.CN's P/E ratio is -4.20. In terms of profitability, MMED.NE's ROE is -0.33%, compared to PHRM.CN's ROE of -0.83%. Regarding short-term risk, MMED.NE is more volatile compared to PHRM.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs REUN.TO Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, REUN.TO has a market cap of 16.6M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while REUN.TO trades at CA$1.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas REUN.TO's P/E ratio is -0.43. In terms of profitability, MMED.NE's ROE is -0.33%, compared to REUN.TO's ROE of -1.10%. Regarding short-term risk, MMED.NE is more volatile compared to REUN.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs TELI.CN Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, TELI.CN has a market cap of 15.8M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while TELI.CN trades at CA$0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas TELI.CN's P/E ratio is -9.83. In terms of profitability, MMED.NE's ROE is -0.33%, compared to TELI.CN's ROE of -2.08%. Regarding short-term risk, MMED.NE is more volatile compared to TELI.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs IMV.TO Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, IMV.TO has a market cap of 13.1M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while IMV.TO trades at CA$1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas IMV.TO's P/E ratio is -0.18. In terms of profitability, MMED.NE's ROE is -0.33%, compared to IMV.TO's ROE of -4.95%. Regarding short-term risk, MMED.NE is more volatile compared to IMV.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs RVX.TO Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, RVX.TO has a market cap of 12.8M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while RVX.TO trades at CA$0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas RVX.TO's P/E ratio is -4.50. In terms of profitability, MMED.NE's ROE is -0.33%, compared to RVX.TO's ROE of +0.06%. Regarding short-term risk, MMED.NE is more volatile compared to RVX.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs BETR.CN Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, BETR.CN has a market cap of 12.3M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while BETR.CN trades at CA$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas BETR.CN's P/E ratio is -3.17. In terms of profitability, MMED.NE's ROE is -0.33%, compared to BETR.CN's ROE of +0.43%. Regarding short-term risk, MMED.NE is more volatile compared to BETR.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs GLOW.CN Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, GLOW.CN has a market cap of 12.2M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while GLOW.CN trades at CA$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas GLOW.CN's P/E ratio is -2.00. In terms of profitability, MMED.NE's ROE is -0.33%, compared to GLOW.CN's ROE of +12.80%. Regarding short-term risk, MMED.NE is more volatile compared to GLOW.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs TBP.TO Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, TBP.TO has a market cap of 10.6M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while TBP.TO trades at CA$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas TBP.TO's P/E ratio is -0.31. In terms of profitability, MMED.NE's ROE is -0.33%, compared to TBP.TO's ROE of -4.68%. Regarding short-term risk, MMED.NE is more volatile compared to TBP.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs MDMA.CN Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, MDMA.CN has a market cap of 10M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while MDMA.CN trades at CA$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas MDMA.CN's P/E ratio is -4.75. In terms of profitability, MMED.NE's ROE is -0.33%, compared to MDMA.CN's ROE of -0.86%. Regarding short-term risk, MMED.NE is more volatile compared to MDMA.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs BLAB.CN Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, BLAB.CN has a market cap of 9.7M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while BLAB.CN trades at CA$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas BLAB.CN's P/E ratio is -1.20. In terms of profitability, MMED.NE's ROE is -0.33%, compared to BLAB.CN's ROE of -4.53%. Regarding short-term risk, MMED.NE is more volatile compared to BLAB.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs BIOV.CN Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, BIOV.CN has a market cap of 8.7M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while BIOV.CN trades at CA$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas BIOV.CN's P/E ratio is -1.50. In terms of profitability, MMED.NE's ROE is -0.33%, compared to BIOV.CN's ROE of +4.49%. Regarding short-term risk, MMED.NE is less volatile compared to BIOV.CN. This indicates potentially lower risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs MCUR.CN Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, MCUR.CN has a market cap of 7M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while MCUR.CN trades at CA$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas MCUR.CN's P/E ratio is -0.75. In terms of profitability, MMED.NE's ROE is -0.33%, compared to MCUR.CN's ROE of -1.61%. Regarding short-term risk, MMED.NE is more volatile compared to MCUR.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs COOL.CN Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, COOL.CN has a market cap of 6.8M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while COOL.CN trades at CA$0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas COOL.CN's P/E ratio is -1.32. In terms of profitability, MMED.NE's ROE is -0.33%, compared to COOL.CN's ROE of -2.90%. Regarding short-term risk, MMED.NE is more volatile compared to COOL.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs APS.TO Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, APS.TO has a market cap of 6M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while APS.TO trades at CA$2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas APS.TO's P/E ratio is -0.10. In terms of profitability, MMED.NE's ROE is -0.33%, compared to APS.TO's ROE of +3.67%. Regarding short-term risk, MMED.NE is more volatile compared to APS.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs TRYP.CN Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, TRYP.CN has a market cap of 5.8M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while TRYP.CN trades at CA$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas TRYP.CN's P/E ratio is -1.50. In terms of profitability, MMED.NE's ROE is -0.33%, compared to TRYP.CN's ROE of +4.03%. Regarding short-term risk, MMED.NE is more volatile compared to TRYP.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs ASEP.CN Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, ASEP.CN has a market cap of 5.6M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while ASEP.CN trades at CA$0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas ASEP.CN's P/E ratio is -0.83. In terms of profitability, MMED.NE's ROE is -0.33%, compared to ASEP.CN's ROE of -0.40%. Regarding short-term risk, MMED.NE is more volatile compared to ASEP.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs CMND.CN Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, CMND.CN has a market cap of 5.1M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while CMND.CN trades at CA$1.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas CMND.CN's P/E ratio is -0.04. In terms of profitability, MMED.NE's ROE is -0.33%, compared to CMND.CN's ROE of -0.46%. Regarding short-term risk, MMED.NE is more volatile compared to CMND.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs GTTX.CN Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, GTTX.CN has a market cap of 4.6M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while GTTX.CN trades at CA$0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas GTTX.CN's P/E ratio is -12.00. In terms of profitability, MMED.NE's ROE is -0.33%, compared to GTTX.CN's ROE of -0.60%. Regarding short-term risk, MMED.NE is more volatile compared to GTTX.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs AWKN.NE Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, AWKN.NE has a market cap of 3.9M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while AWKN.NE trades at CA$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas AWKN.NE's P/E ratio is -0.36. In terms of profitability, MMED.NE's ROE is -0.33%, compared to AWKN.NE's ROE of -4.29%. Regarding short-term risk, MMED.NE is more volatile compared to AWKN.NE. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs MYND.CN Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, MYND.CN has a market cap of 3.3M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while MYND.CN trades at CA$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas MYND.CN's P/E ratio is -3.50. In terms of profitability, MMED.NE's ROE is -0.33%, compared to MYND.CN's ROE of +0.18%. Regarding short-term risk, MMED.NE is less volatile compared to MYND.CN. This indicates potentially lower risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs IPCI.TO Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, IPCI.TO has a market cap of 2.6M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while IPCI.TO trades at CA$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas IPCI.TO's P/E ratio is -0.67. In terms of profitability, MMED.NE's ROE is -0.33%, compared to IPCI.TO's ROE of +0.31%. Regarding short-term risk, MMED.NE is more volatile compared to IPCI.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs APLI.TO Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, APLI.TO has a market cap of 2.4M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while APLI.TO trades at CA$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas APLI.TO's P/E ratio is -0.75. In terms of profitability, MMED.NE's ROE is -0.33%, compared to APLI.TO's ROE of +0.32%. Regarding short-term risk, MMED.NE is more volatile compared to APLI.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs AGN.CN Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, AGN.CN has a market cap of 2M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while AGN.CN trades at CA$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas AGN.CN's P/E ratio is 2.67. In terms of profitability, MMED.NE's ROE is -0.33%, compared to AGN.CN's ROE of +0.15%. Regarding short-term risk, MMED.NE is more volatile compared to AGN.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs MOOD.CN Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, MOOD.CN has a market cap of 1.8M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while MOOD.CN trades at CA$0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas MOOD.CN's P/E ratio is -6.67. In terms of profitability, MMED.NE's ROE is -0.33%, compared to MOOD.CN's ROE of -0.28%. Regarding short-term risk, MMED.NE is more volatile compared to MOOD.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs ENBI.CN Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, ENBI.CN has a market cap of 1.5M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while ENBI.CN trades at CA$0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas ENBI.CN's P/E ratio is -2.75. In terms of profitability, MMED.NE's ROE is -0.33%, compared to ENBI.CN's ROE of -1.33%. Regarding short-term risk, MMED.NE is more volatile compared to ENBI.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs LEXT.CN Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, LEXT.CN has a market cap of 1.5M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while LEXT.CN trades at CA$0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas LEXT.CN's P/E ratio is -0.69. In terms of profitability, MMED.NE's ROE is -0.33%, compared to LEXT.CN's ROE of -2.39%. Regarding short-term risk, MMED.NE is more volatile compared to LEXT.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs BRAX.CN Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, BRAX.CN has a market cap of 1.4M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while BRAX.CN trades at CA$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas BRAX.CN's P/E ratio is -0.10. In terms of profitability, MMED.NE's ROE is -0.33%, compared to BRAX.CN's ROE of -2.49%. Regarding short-term risk, MMED.NE is more volatile compared to BRAX.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs HAVN.CN Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, HAVN.CN has a market cap of 1.2M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while HAVN.CN trades at CA$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas HAVN.CN's P/E ratio is -0.01. In terms of profitability, MMED.NE's ROE is -0.33%, compared to HAVN.CN's ROE of +0.00%. Regarding short-term risk, MMED.NE is more volatile compared to HAVN.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs CHGX.CN Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, CHGX.CN has a market cap of 415.6K. Regarding current trading prices, MMED.NE is priced at CA$14.90, while CHGX.CN trades at CA$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas CHGX.CN's P/E ratio is -0.50. In terms of profitability, MMED.NE's ROE is -0.33%, compared to CHGX.CN's ROE of +0.23%. Regarding short-term risk, MMED.NE is more volatile compared to CHGX.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs CURE.CN Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, CURE.CN has a market cap of 408K. Regarding current trading prices, MMED.NE is priced at CA$14.90, while CURE.CN trades at CA$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas CURE.CN's P/E ratio is 0.17. In terms of profitability, MMED.NE's ROE is -0.33%, compared to CURE.CN's ROE of -2.58%. Regarding short-term risk, MMED.NE is more volatile compared to CURE.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs ABRT.CN Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, ABRT.CN has a market cap of 372.1K. Regarding current trading prices, MMED.NE is priced at CA$14.90, while ABRT.CN trades at CA$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas ABRT.CN's P/E ratio is -0.10. In terms of profitability, MMED.NE's ROE is -0.33%, compared to ABRT.CN's ROE of +16.27%. Regarding short-term risk, MMED.NE is more volatile compared to ABRT.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs NSHS.CN Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, NSHS.CN has a market cap of 359.6K. Regarding current trading prices, MMED.NE is priced at CA$14.90, while NSHS.CN trades at CA$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas NSHS.CN's P/E ratio is 0.88. In terms of profitability, MMED.NE's ROE is -0.33%, compared to NSHS.CN's ROE of +0.09%. Regarding short-term risk, MMED.NE is more volatile compared to NSHS.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs WBIO.CN Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, WBIO.CN has a market cap of 324.8K. Regarding current trading prices, MMED.NE is priced at CA$14.90, while WBIO.CN trades at CA$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas WBIO.CN's P/E ratio is 0.41. In terms of profitability, MMED.NE's ROE is -0.33%, compared to WBIO.CN's ROE of +0.01%. Regarding short-term risk, MMED.NE is more volatile compared to WBIO.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs NIRV.CN Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, NIRV.CN has a market cap of 289.4K. Regarding current trading prices, MMED.NE is priced at CA$14.90, while NIRV.CN trades at CA$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas NIRV.CN's P/E ratio is -0.30. In terms of profitability, MMED.NE's ROE is -0.33%, compared to NIRV.CN's ROE of +0.00%. Regarding short-term risk, MMED.NE is more volatile compared to NIRV.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs NOVA.CN Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, NOVA.CN has a market cap of 148.3K. Regarding current trading prices, MMED.NE is priced at CA$14.90, while NOVA.CN trades at CA$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas NOVA.CN's P/E ratio is -0.05. In terms of profitability, MMED.NE's ROE is -0.33%, compared to NOVA.CN's ROE of -0.02%. Regarding short-term risk, MMED.NE is more volatile compared to NOVA.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs TRIL.TO Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, TRIL.TO has a market cap of 0. Regarding current trading prices, MMED.NE is priced at CA$14.90, while TRIL.TO trades at CA$23.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas TRIL.TO's P/E ratio is -34.06. In terms of profitability, MMED.NE's ROE is -0.33%, compared to TRIL.TO's ROE of -0.43%. Regarding short-term risk, MMED.NE is more volatile compared to TRIL.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.
MMED.NE vs IN.TO Comparison
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, IN.TO has a market cap of 0. Regarding current trading prices, MMED.NE is priced at CA$14.90, while IN.TO trades at CA$4.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas IN.TO's P/E ratio is -2.77. In terms of profitability, MMED.NE's ROE is -0.33%, compared to IN.TO's ROE of -162.30%. Regarding short-term risk, MMED.NE is more volatile compared to IN.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.